These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 15010892)

  • 1. Breast cancer after curative chemotherapy in non-Hodgkin's lymphoma: examination of the role of drug resistance and retrospective comparison to the outcome of de novo breast cancer.
    Tsavaris N; Kosmas C; Zorzos H; Lazaris A; Vadiaka M; Dimitrakopoulos A; Siakantaris MP; Rokana S; Papalambros E; Pangalis GA; Davaris P
    Oncol Rep; 2004 Apr; 11(4):899-903. PubMed ID: 15010892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breast cancer following curative chemotherapy for non-Hodgkin's lymphoma and the effect of drug resistance proteins to the final outcome. A retrospective study.
    Tsavaris N; Kosmas C; Kavantzas N; Lazaris A; Skopelitis E; Dimitrakopoulos A; Siakantaris MP; Papalambros E; Diamantis N; Patsouris E; Pangalis GA
    J BUON; 2005; 10(1):71-6. PubMed ID: 17335134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of optimal treatment on elderly patients with aggressive non-Hodgkin's lymphoma: more patients treated with unaffected response rates.
    Peters FP; Fickers MM; Erdkamp FL; Wals J; Wils JA; Schouten HC
    Ann Hematol; 2001 Jul; 80(7):406-10. PubMed ID: 11529466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effective immunochemotherapy for aggressive non-Hodgkin's lymphoma.
    Coiffier B
    Semin Oncol; 2004 Feb; 31(1 Suppl 2):7-11. PubMed ID: 15042528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
    Zou GR; Zhang YJ; Xie FY; Zheng W; Li HX; Xia YF; Lin TY; Lu TX
    Ai Zheng; 2006 Dec; 25(12):1543-9. PubMed ID: 17166383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Survival of patients with aggressive non-hodgkin's lymphoma: no difference between first line treatment in a prospective randomised phase III clinical trial and first line treatment according to routine clinical practice].
    van Agthoven M; Wittebol S; Budel LM; Uyl-de Groot CA; Kramer MH
    Ned Tijdschr Geneeskd; 2004 Jan; 148(2):88-93. PubMed ID: 14753131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Expression and significance of P-gp/mdr1 mRNA, MRP and LRP in non-Hodgkin's lymphoma].
    Li L; Su LP; Ma L; Zhao J; Zhu L; Zhou YA
    Zhonghua Zhong Liu Za Zhi; 2009 Mar; 31(3):199-202. PubMed ID: 19615260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma.
    Verdonck LF; van Putten WL; Hagenbeek A; Schouten HC; Sonneveld P; van Imhoff GW; Kluin-Nelemans HC; Raemaekers JM; van Oers RH; Haak HL
    N Engl J Med; 1995 Apr; 332(16):1045-51. PubMed ID: 7898521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma glutathione S-Transferase P1-1 as a prognostic factor in patients with advanced non-Hodgkin's lymphoma (stages III and IV).
    Katahira T; Takayama T; Miyanishi K; Hayashi T; Ikeda T; Takahashi Y; Takimoto R; Matsunaga T; Kato J; Niitsu Y
    Clin Cancer Res; 2004 Dec; 10(23):7934-40. PubMed ID: 15585627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective comparison between CHOP-PVP and CHOP protocols for non-Hodgkin's lymphoma.
    Gan H; Zhang F; Lin Y
    Zhonghua Zhong Liu Za Zhi; 2002 Jul; 24(4):397-9. PubMed ID: 12408775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical comparison of CHO regimen versus CHOP regimen for treatment of patients with intermediate-grade non-Hodgkin's lymphoma].
    Yuan ZY; Xu RH; He YJ; Guan ZZ
    Ai Zheng; 2003 Apr; 22(4):393-6. PubMed ID: 12703996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy with MECOP-B for intermediate-grade and high-grade non-Hodgkin's lymphoma in Saudi Arabia: clinical results and analysis of prognostic factors.
    Ibrahim EM; Bunyan RF; al-Mulhim FA; al-Nabhan AA; Ibrahim RE
    Acta Haematol; 1996; 96(3):126-34. PubMed ID: 8876608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prognosis of primary non-Hodgkin's lymphoma of the breast].
    Guo HY; Zhao XM; Cao JN; Hu XC; Yin JL; Hong XN; Li J
    Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):200-2. PubMed ID: 18756936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma.
    Intragumtornchai T; Bunworasate U; Nakorn TN; Rojnuckarin P
    Leuk Lymphoma; 2006 Jul; 47(7):1306-14. PubMed ID: 16923561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multidrug resistance (MDR-1) expression in AIDS-related lymphomas.
    Tulpule A; Sherrod A; Dharmapala D; Young LL; Espina BM; Sanchez MN; Gill PS; Levine AM
    Leuk Res; 2002 Feb; 26(2):121-7. PubMed ID: 11755462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delivery of full dose CHOP chemotherapy to elderly patients with aggressive non-Hodgkin's lymphoma without G-CSF support.
    Campbell C; Sawka C; Franssen E; Berinstein NL
    Leuk Lymphoma; 1999 Sep; 35(1-2):119-27. PubMed ID: 10512169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I/II trial of nonpegylated liposomal doxorubicin, cyclophosphamide, vincristine, and prednisone in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma.
    Tulpule A; Espina BM; Berman N; Buchanan LH; Smith DL; Sherrod A; Dharmapala D; Gee C; Boswell WD; Nathwani BN; Welles L; Levine AM
    Clin Lymphoma Myeloma; 2006 Jul; 7(1):59-64. PubMed ID: 16879771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CHOP Chemotherapy for Aggressive Non-Hodgkin Lymphoma with and without HIV in the Antiretroviral Therapy Era in Malawi.
    Gopal S; Fedoriw Y; Kaimila B; Montgomery ND; Kasonkanji E; Moses A; Nyasosela R; Mzumara S; Varela C; Chikasema M; Makwakwa V; Itimu S; Tomoka T; Kamiza S; Dhungel BM; Chimzimu F; Kampani C; Krysiak R; Richards KL; Shea TC; Liomba NG
    PLoS One; 2016; 11(3):e0150445. PubMed ID: 26934054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary extranodal non-Hodgkin's lymphoma: clinicopathological features, survival and treatment outcome in two cancer centers of southern Turkey.
    Mertsoylu H; Muallaoglu S; Besen AA; Erdogdu S; Sezer A; Sedef AM; Kose F; Arican A; Ozyilkan O
    Asian Pac J Cancer Prev; 2014; 15(17):7207-11. PubMed ID: 25227815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.